Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Net Cash Position ⢠Solid Margins ⢠Cash Conversion TCMD has a strong balance sheet and solid profitability, but moderate valuation and weaker quarterly cash conversion warrant selective optimism.
Price Behavior
Key Price Behavior Insights: ⢠Sharp monthly decline ⢠Oversold momentum ⢠Key support test Support Level: $21.87 Resistance Level: $22.98â$23.16 TCMD is bearish after falling 26% last month, but oversold RSI may support a rebound if it holds $21.87 and clears $22.98â$23.16.
Sentiment & News
Key News Insights: ⢠Earnings beat ⢠Lymphedema momentum ⢠Airway pressure TCMD's Q2 beat and lymphedema-driven growth are positive, though airway-clearance inventory headwinds temper the full-year outlook.
AI Summary
TCMD is now an execution-and-mix investment: strong lymphedema growth, high margins, and a net-cash balance sheet support upside, but investors should wait for proof that airway-clearance weakness is temporary and free-cash-flow conversion recovers before treating the new device as a meaningful growth catalyst.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |